Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-18
2011-01-18
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388800
Reexamination Certificate
active
07872105
ABSTRACT:
A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.
REFERENCES:
patent: 5593847 (1997-01-01), Barnett et al.
patent: 5777078 (1998-07-01), Bayley et al.
patent: 5798218 (1998-08-01), Buckley
patent: 5817771 (1998-10-01), Bayley et al.
patent: 5824776 (1998-10-01), Bayley et al.
patent: 5874298 (1999-02-01), Johnson et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 2002/0039581 (2002-04-01), Carreno et al.
patent: 2002/0045736 (2002-04-01), Yu et al.
patent: 2002/0077454 (2002-06-01), Yu et al.
patent: WO 94/25616 (1994-11-01), None
patent: WO 96/20688 (1996-07-01), None
patent: WO 97/20932 (1997-06-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 00/52054 (2000-09-01), None
patent: WO 00/58335 (2000-10-01), None
patent: WO 01/85777 (2001-11-01), None
patent: WO 03/018611 (2003-03-01), None
patent: WO 03/046560 (2003-06-01), None
patent: WO 03/048304 (2003-06-01), None
patent: WO 03/055527 (2003-07-01), None
patent: WO 2004/078097 (2004-09-01), None
Harmsen et al, Appl Microbiol Bioteclinol, 2007, 77:13-22.
Rudikoff et al, Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
MacCallum et al, J. Mol. Biol., 262, 732-745, 1996.
Casset et al, Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Coleman P. M., Research in Immunology, 145:33-36, 1994.
Definition of contiguous, Merriam Webster online dictionary, Jan. 31, 2009.
Brichory, F., et al., “Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen . . . ” Cancer Research (2001) 61:7908-7912.
Casset, F., et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design” Biochemical and Biophysical Research Communication (2003) 307:198-205.
Colman, P.M., et al., Effects of amino acid sequence changes on antibody-antigen interactions Biomolecular Research Inst. (1994) 145:33-36.
Efimov, V.P., et al., “The thrombospondin-like chains of cartilage oligomeric matrix . . . ” Biophysical Chemistry (1994) 341″54-58.
Els Conrath, K., et al., “Camel Single-domain Antibodies as Modular Building . . . ” Biological Chemistry (2001) 276:7346-7350.
Frankel, A.E., et al., “Antibody-Toxin Hybrids: A Clinical Review of their use” Biological Response Modifiers (1985) 4:437-446.
Griffiths, A.D., et al., “Isolation of high affinity human antibodies directly . . . ” EMBO Journal (1994) 13:3245-3260.
Hoogenboom, H.R., et al., “Natural and disgner binding sites made by phage display technology” Immunology (2000) 21:371-378.
Howard, S.P., et al., “Nucleotide Sequence of the Gene for the Hole-Forming . . . ” Journal of Bacteriology (1987) 169:2869-2871.
Hudson, P.J., et al., “High avidity scFv multimers; diabodies and triabodies” Journal of Immunological Methods (1999) 231:177-189.
Kaminski, M.J., et al., “The Role of Homophilic Binding in Anti-tumor Antibody . . . ” Biological Chemistry (1999) 274:5597-5604.
Kitov, P.I., et al., “Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands” Letters to Nature (2000) 403:669-672.
Ling, H., et al., “Structure of the Shiga-like toxin I B-Pentamer Complexed with an Analogue . . . ” Biochemistry (1998) 37:1777-1788.
MacCallum, R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography” J.Mol. Biol. (1996) 262:732-745.
McCafferty, J., et al., “Phage antibodies: filamentous phage displaying antibody variable domains” Nature ( 1990) 348:552-554.
Menon, L.G., et al., “Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds” Cancer Letters (1995) 95:221-225.
Ohlin, M., et al., “Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition” Molecular Immunology (1996) 33:47-56.
Pluckthun, A., et al., “New protein engineering approaches to multivalent and bispecific antibody fragments” Immunotechnology (1997) 3:83-105.
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity” Proc. Natl. Acad. Sci (1982) 79:1979-1983.
Schier, R., et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution . . . ” J. Mol. Biol. (1996) 263:551-567.
Skerra, A., et al., “The functional expression of antibody Fv Fragments inEscherichia coli: . . . ” Nature Publishing Group (1991) 9:273-278.
Soltyk, A.M., et al., “A Mutational Analysis of the Globotriaosylceramide-binding Sites of Verotoxin VT1” Biological Chemistry (2002) 277:5351-5359.
Spyres, L.M., et al. “Cytosolic Delivery and Characterization of the TedB Glucosylating Domain by Using a Heterologous Protein Fusion” Infection and Immunity (2001) 69:599-601.
Tanha, J., et al., “Optimal Design Features of Camelized Human Single-domain Anitbody Libraries” Biological Chemistry (2001) 276:24772-24780.
Tanha, J., et al., “Selection by Phage display of llama conventional VH fragments with heavy . . . ” Immunological Methods (2002) 263:97-109.
Tanha, J., et al., “Phage Display Technology for Identifying Specific Antigens on Brain Endothelial Cells” Methods in Molecular Medicine (2003) 89:435-449.
Terskikh, A.V., et al., “Peptabody: A New type of high avidity binding protein” Proc. Natil. Acad. Sci. (1997) 94:1663-1668.
Willuda, J., et al., “High Thermal Stability is Essential for Tumor Targeting of Antibody Fragments: . . . ” Cancer Research (1999) 59:5758-5767.
Yang, W.P., et al., “CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range” Mol. Biol. (1995) 254:392-403.
Zhang, J., et al., “Pentamerization of Single-domain Antibodies from Phage Libraries: . . . ” Mol. Biol. (2004) 335:49-56.
Zhang, J., et al., “A Pentavalent Single-domain Antibody Approach to Tumor Antigen Discovery and the . . . ” J. Mol. Biol. (2004) 341:161-169.
Zimmermann, S., et al., “A novel immunotoxin recognising the epithellal glycoprotein-2 has potent antitumoural . . . ” Cancer Immunol Immunother (1997) 44:1-9.
Jantscheff, P., “Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance” Nal. of Clinical Oncology (2003) 21:3638-3646.
Kuroki, M., et al., “Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker” Anticancer Research (1999) 19:5599-5606.
Pimenidou, A., et al., “Bacteriophage-derived antibodies in cancer research-diagnosis imaging and treatment” Disease Markers (2000) 16:41-51.
Schoelzel, S., et al., “Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed . . . ” American Journal of Pathology (2000) 156:595-605.
Li Qinggang
Mackenzie Colin Roger
Mai Kien Trung
Nguyen Thanh-Dung
Zhang Jianbing
Halvorson Mark
Koeing Hans
National Research Council of Canada
Ottawa Hospital Research Institute
Patenaude Sonia
LandOfFree
Anticarcinoma antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticarcinoma antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticarcinoma antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2622411